To hear about similar clinical trials, please enter your email below

Trial Title: Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer

NCT ID: NCT00855998

Condition: Breast Cancer
Ovarian Cancer

Conditions: Official terms:
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial

Conditions: Keywords:
Thymidine Kinase 1
BRCA1 and BRCA2 mutations
hereditary breast/ovarian cancer

Study type: Observational

Overall status: Unknown status

Study design:

Time perspective: Prospective

Summary: This study aimed to compare the activity of Thymidine Kinase 1 in serum of two groups of woman at high and normal risk for breast/ovary cancer.

Detailed description: Hereditary breast/ovarian cancer syndrome is associated with mutations in tumor suppressor BRCA1 and BRCA2 genes. Products of these genes play an important role in the repair of DNA double-strand breaks. Mutations in BRCA1 and BRCA2 genes could impair DNA repair. In resting or G1 cells, where the de novo synthesis of DNA precursors is absent, the salvage pathway is the sole provider of deoxyribonucleotides to be used in DNA repair. For this process a sufficient supply of deoxynucleotides and activity of Thymidine Kinase 1 are essential. TK1 is an important component of adaptive response of cells to DNA damage. Mutations in genes directly engaged in the DNA repair process could lead to the accumulation of DNA damage and in turn cause an adaptive cell reaction manifesting as permanently increased Thymidine Kinase 1 activity. A recently developed new high-sensitive assay DiviTum® allows to investigate the contribution of this enzyme to DNA repair processes and to make a comparison of Thymidine kinase 1 activity in women with normal and impared DNA repair system.

Criteria for eligibility:

Study pop:
women visiting the outpatient oncology clinic for genetic/familial high-risk assessments

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - women from family with more than two breast cancer cases and one or more cases of ovarian cancer diagnosed at any age; - women from family with more than three breast cancer cases diagnosed before the age 50; - women from family withsister pair in which one of the following combinations was diagnosed before the age of 50: two breast cancers, two ovarian cancers, or a breast and ovarian cancer. Exclusion Criteria:• - pregnant women; - women with generalized CMV and HZV infections; - women with severe B12 deficiency and megaloblastic anaemia; - women with severe rheumatoid arthritis.

Gender: Female

Minimum age: 18 Years

Maximum age: 80 Years

Healthy volunteers: Accepts Healthy Volunteers

Locations:

Facility:
Name: Hadassah Medical Organization

Address:
City: Jerusalem
Zip: 91120
Country: Israel

Status: Recruiting

Contact:
Last name: Arik Tzukert, DMD

Phone: 6776095

Phone ext: 00 972 2
Email: arik@hadassah.org.il

Investigator:
Last name: Benjamin Nisman, PhD
Email: Sub-Investigator

Start date: March 2009

Completion date: March 2011

Lead sponsor:
Agency: Hadassah Medical Organization
Agency class: Other

Source: Hadassah Medical Organization

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT00855998

Login to your account

Did you forget your password?